ReviewEuropean child & adolescent psychiatry2012
Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options.
Review in European child & adolescent psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02063945 (The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders), which is not on this map. Cited by 65 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
Who cites it
65 citing papers in PubMed, 4 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Medication adherence and influencing factors in children and adolescents with attention deficit hyperactivity disorder (ADHD): a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Pooled it
- Amphetamine Use in the Elderly: A Systematic Review of the Literature.Current neuropharmacology · 2020Pooled it
- Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.BMC medicine · 2016Pooled it
- Trial
- Improving Methylphenidate Titration in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): A Randomized Controlled Trial Using Placebo-Controlled Titration Implemented in Clinical Practice.Paediatric drugs · 2024Trial
- Dorsal-to-ventral imbalance in the superior longitudinal fasciculus mediates methylphenidate's effect on beta oscillations in ADHD.Psychophysiology · 2022Trial
- Trial
- Trial
- Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.Journal of child and adolescent psychopharmacology · 2014Trial
- Acute neuropharmacological effects of atomoxetine on inhibitory control in ADHD children: a fNIRS study.NeuroImage. Clinical · 2014Trial
- Trial
- Trial
- ADHD medications and preadolescent brain structure: patterns of cortical attenuation from the ABCD study.Scientific reports · 2026Article
- Innovative Nanomaterial-Based Approaches for the Recognition of Amphetamine in Attention Deficit Hyperactivity Disorder Management.Analytical science advances · 2026Review
- Digital health technologies for adults with ADHD: a scoping review.Frontiers in digital health · 2026Review
- County-level variation and trajectories in ADHD medication dispensing among Norwegian children and adolescents, 2005-2022: a nationwide prescription register study.Frontiers in psychiatry · 2026Article
- Stimulant medication and symptom interrelations in children, adolescents and adults with attention-deficit/hyperactivity disorder.European child & adolescent psychiatry · 2025Article
- Genetic and Regulatory Mechanisms of Comorbidity of Anxiety, Depression and ADHD: A GWAS Meta-Meta-Analysis Through the Lens of a System Biological and Pharmacogenomic Perspective in 18.5 M Subjects.Journal of personalized medicine · 2025Article
- Economic Evaluation of Extended-Release Amphetamine (Dyanavel XR) Among Individuals with Attention-Deficit/Hyperactivity Disorder From a United States Societal Perspective.ClinicoEconomics and outcomes research : CEOR · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders among school-aged children. It is highly symptomatic and associated with significant impairment. This review examines the role of stimulant medications in the treatment of children and adolescents with ADHD. Published clinical studies that compared methylphenidate- and amfetamine-based stimulants in children and adolescents with ADHD support the therapeutic utility of stimulant treatments, and suggest robust efficacy and acceptable safety outcomes in groups treated with either stimulant. Evidence-based guidelines agree that each patient with ADHD is unique and individual treatment strategies that incorporate both drug and non-drug treatment options should be sought. In seeking to optimize individual response and outcomes to stimulant therapy, important considerations include the selection of stimulant class, the choice of long- or short-acting stimulant formulations, addressing effectively any emergent adverse effects and strategies aimed at enhancing adherence to dosing regimen and persistence on therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.